AMENDMENTS TO THE CLAIMS

1. **(Cancelled)**

2. **(Original)** A pharmaceutical composition comprising C-peptide together with at least one pharmaceutically acceptable carrier or excipient for administration to a patient as a once daily dose, wherein said once daily dose does not include a continuous administration or the presence of release rate-controlling agents for the treatment of diabetes and/or microvascular diabetic complications.

3. **(Currently amended)** ~~Method~~ A method of treating diabetes and/or microvascular diabetic complications comprising administering C-peptide or a pharmaceutical composition comprising C-peptide to a patient in a once daily dose, wherein said once daily dose does not include a continuous administration or the presence of release rate-controlling agents.

4. **(Currently amended)** ~~Use,~~ The pharmaceutical composition ~~or method~~ according to Claim 2 ~~any one of claims 1 to 3~~ wherein the C-peptide is human C-peptide

5. **(Currently amended)** ~~Use,~~ The pharmaceutical composition ~~or method~~ according to Claim 2 ~~any one of claims 1 to 4~~ wherein said C-peptide is a ~~the~~ fragment EGSLQ (SEQ ID NO:~~[[-]]~~ 2).

6. **(Currently amended)** ~~Use,~~ The pharmaceutical composition ~~or method~~ according to Claim 2 ~~any one of claims 1 to 5~~ wherein the patient is a human.

7. **(Currently amended)** ~~Use,~~ The pharmaceutical composition ~~or method~~ according to Claim 2 ~~any one of claims 1 to 6~~ wherein the medicament contains 100 to 1800 nmol of C-peptide.

8. **(Currently amended)** ~~Use,~~ The pharmaceutical composition ~~or method~~ according to Claim 2 ~~any one of claims 1 to 7~~ wherein the medicament is an uncompromised aqueous solution.

9. **(Currently amended)** ~~Use,~~ The pharmaceutical composition ~~or method~~ according to Claim 2 ~~any one of claims 1 to 8~~ wherein said complications are diabetic nephropathy, retinopathy or neuropathy.

10. **(New)** The method according to Claim 3, wherein the C-peptide is human C-peptide

11. **(New)** The method according to Claim 3, wherein said C-peptide is a fragment EGSLQ (SEQ ID NO: 2).

12. **(New)** The method according to Claim 3, wherein the patient is a human.

13. **(New)** The method according to Claim 3, wherein the medicament contains 100 to 1800 nmol of C- peptide.

14. **(New)** The method according to Claim 3, wherein the medicament is an uncompromised aqueous solution.

15. **(New)** The method according to Claim 3, wherein said complications are diabetic nephropathy, retinopathy or neuropathy.